ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg Label

About this update from Ars Pharmaceuticals, Inc.

SAN DIEGO - ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the U.S. Food and Drug Administration (FDA) has approved updating the neffy 1 mg prescribing information to remove the age criteria so all children and adults who weigh 33 lbs. or more can utilize neffy for the emergency treatment of Type 1 allergic reactions, including anaphylaxis. Prior to the update, pediatric patients needed to meet a weight requirement and be at least four years of age. Additionally, the label update recommends patients carry neffy in the blister packaging or in the neffy carrying case. The company currently offers patients a case designed specifically to hold two neffy devices, free of charge, at www.neffy.com and will begin including the carrying case in each prescription carton this summer. 'We are very pleased that based on clinical data presented to FDA for neffy, that the Agency removed the age requirement in the indication. This is a major advancement for the families with small children who live with the constant worry of severe allergic reactions in their youngest children,' said Richard Lowenthal , Co-Founder, President, and CEO of ARS Pharma. 'Approximately one-quarter of patients requiring epinephrine are children weighing =33 lbs. and (C) 2026 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Ars Pharmaceuticals, Inc.